# SAILIFE (SAILIFE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/sailife

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,597.6
- Change: +3.36%
- As of: 2026-09-18
- 1D return: +3.55%
- 5D return: +0.59%
- 1M return: +8.76%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 17, 2026, the stock is trading above key moving averages across daily, weekly, and monthly timeframes, indicating a generally bullish technical stance. The daily trend shows a strong uptrend with the ADX at 34.31 and the Supertrend indicator in a bullish state. This aligns with the monthly timeframe, which also exhibits a bullish Supertrend and a high ADX of 75.02, suggesting sustained upward momentum over a longer period. The weekly timeframe also supports this with a bullish Supertrend and positive moving average relationships. A recent "Bullish Engulfing Reversal" pattern was observed on the daily chart on September 17, 2026.

Nearest support is identified around ₹1530.43 (pivot level), followed by ₹1503.07. Resistance is observed at ₹1566.47, with further levels at ₹1593.83 and ₹1629.87. The stock's current price of ₹1545.7 is positioned within its recent trading range, with the position in the 252-day range at 83%. The annualized volatility stands at 38%, and the current drawdown is -8%.

Key watch conditions include monitoring the stock's ability to hold above the ₹1530.43 support level. A sustained move above the nearest resistance at ₹1566.47 could signal further upside. Conversely, a break below the ₹1503.07 support level may indicate a weakening of the current bullish trend.

- The stock's technical posture is bullish, supported by price relationships above key moving averages on daily, weekly, and monthly charts.
- Nearest support levels are ₹1530.43 and ₹1503.07.
- Nearest resistance levels are ₹1566.47 and ₹1593.83.
- A "Bullish Engulfing Reversal" pattern was noted on the daily chart on September 17, 2026.
- Watch for a sustained move above ₹1566.47 or a break below ₹1503.07 for potential trend confirmation or reversal.

- Bullish Engulfing Reversal
- Doji
- Bearish Engulfing Reversal
- Inside Bar

### News Context

Sai Life Sciences Limited held its 27th Annual General Meeting (AGM) on September 17, 2026. During the meeting, shareholders approved the audited standalone and consolidated financial statements for the fiscal year ending March 31, 2026, with nearly unanimous support (99.9999% of votes polled). Additionally, Mr. Krishnamraju Kanumuri was re-appointed as a director, receiving 99.0189% of the votes polled in favor. The company also participated in investor events during the week. On September 4, 2026, Sai Life Sciences announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026, and the Jefferies 5th India Forum in Gurgaon on September 18, 2026, engaging in group and one-to-one meetings with institutional investors.

- On September 17, 2026, Sai Life Sciences' 27th AGM saw shareholders approve the financial statements for the year ended March 31, 2026, with 99.9999% of votes in favor.
- Mr. Krishnamraju Kanumuri was re-appointed as a director at the AGM on September 17, 2026, with 99.0189% of votes supporting the resolution.
- The company participated in the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026.
- Sai Life Sciences also attended the Jefferies 5th India Forum in Gurgaon on September 18, 2026, for investor meetings.

- Sai Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026 |SUBJECT: Shareholders meeting
- Sai Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Sai Life Sciences Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Sai Life Sciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates

### What Changed

On September 17, 2026, Sai Life Sciences Limited held its 27th Annual General Meeting (AGM), where shareholders approved two ordinary resolutions. The audited standalone and consolidated financial statements for the year ended March 31, 2026, were adopted with over 99.99% of votes in favor. Additionally, Mr. Krishnamraju Kanumuri was re-appointed as a director, receiving approximately 99.02% of the votes polled. The company's stock saw a slight increase on September 17, 2026, closing at ₹1545.7 compared to ₹1541.0 on the previous day. This recent activity follows the company's established context as a listed entity on the NSE.

- On September 17, 2026, Sai Life Sciences Limited held its 27th AGM.
- Shareholders approved the financial statements for the year ended March 31, 2026, with 99.9999% of votes in favor.
- Mr. Krishnamraju Kanumuri was re-appointed as a director with 99.0189% of votes in favor on September 17, 2026.
- The stock price closed at ₹1545.7 on September 17, 2026, up from ₹1541.0 on September 16, 2026.

- Sai Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting

### Official Filings

Sai Life Sciences Limited held its 27th Annual General Meeting (AGM) on September 17, 2026. During the meeting, shareholders approved the audited standalone and consolidated financial statements for the fiscal year ending March 31, 2026. Additionally, Mr. Krishnamraju Kanumuri was re-appointed as a director for a tenure extending from September 17, 2026, to September 30, 2029. The company also participated in investor events, including the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026, and the Jefferies 5th India Forum in Gurgaon on September 18, 2026. These forums involved group and one-on-one meetings with institutional investors, with discussions limited to publicly available information.

- On September 17, 2026, Sai Life Sciences Limited's 27th AGM saw the adoption of audited financial statements for the year ended March 31, 2026.
- Mr. Krishnamraju Kanumuri was re-appointed as a director at the AGM, with his tenure set from September 17, 2026, to September 30, 2029.
- Shareholder approval for the financial statements received 99.9999% of votes polled.
- Shareholder approval for Mr. Kanumuri's re-appointment received 99.0189% of votes polled.
- The company engaged with institutional investors at the Morgan Stanley Global Healthcare Conference on September 14, 2026, and the Jefferies India Forum on September 18, 2026.

- Sai Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026 |SUBJECT: Shareholders meeting
- Sai Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Sai Life Sciences Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Sai Life Sciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
- Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication
- Sai Life Sciences Limited has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 17-Sep-2026 |SUBJECT: Notice Of Shareholders Meetings-XBRL
- Sai Life Sciences Limited has informed the Exchange regarding 'Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.'. |SUBJECT: Updates
- Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication

### Fundamentals

Sai Life Sciences, listed on the NSE, reported its financial results for Q1 FY2026-27, showing a sequential decrease in revenue from operations. Revenue stood at ₹554.29 crore in Q1 FY2026-27, down from ₹602.14 crore in the preceding quarter (Q4 FY2025-26) and ₹556.46 crore in Q3 FY2025-26. Profitability also saw a decline, with Profit Before Tax (PBT) at ₹97.97 crore in Q1 FY2026-27, compared to ₹139.23 crore in Q4 FY2025-26 and ₹134.17 crore in Q3 FY2025-26. Consequently, Profit Loss For Period (Net Profit) decreased to ₹73.29 crore in Q1 FY2026-27 from ₹104.24 crore in Q4 FY2025-26 and ₹100.38 crore in Q3 FY2025-26. This trend suggests a contraction in both top-line performance and bottom-line results in the most recent reported quarter. Finance costs remained relatively stable, decreasing slightly from ₹9.70 crore in Q3 FY2025-26 to ₹7.64 crore in Q1 FY2026-27. However, Other Expenses increased sequentially, from ₹67.67 crore in Q3 FY2025-26 to ₹81.47 crore in Q1 FY2026-27, potentially impacting the profit margins. Tax expenses also saw a reduction in Q1 FY2026-27 to ₹24.69 crore from ₹34.99 crore in Q4 FY2025-26, aligning with the lower profit before tax.

- Revenue from operations for Sai Life Sciences was ₹554.29 crore in Q1 FY2026-27.
- Profit Before Tax (PBT) in Q1 FY2026-27 was ₹97.97 crore.
- Net Profit for Q1 FY2026-27 stood at ₹73.29 crore.
- Other Expenses increased sequentially to ₹81.47 crore in Q1 FY2026-27.
- Finance Costs decreased to ₹7.64 crore in Q1 FY2026-27.

### Bull Case

The company's stock is exhibiting strength across multiple timeframes, suggesting a positive operational setup. Daily and weekly technical indicators show a bullish trend, with the Supertrend indicator signaling an upward direction on both daily (1505.1) and weekly (1337.54) charts. The moving averages also indicate positive momentum, with the 20-day Exponential Moving Average (EMA) at 1532.8 and the 50-day Simple Moving Average (SMA) at 1415.67, both below the current closing price of ₹1545.7. On a longer monthly timeframe, the Supertrend is also bullish at 1101.77, with the 20-day EMA at 1045.81. The stock has also demonstrated significant returns over the past year, with a 1-year return of 0.72 and year-to-date (YTD) return of 0.72.

- The stock's daily Supertrend indicator is bullish at 1505.1 as of 2026-09-17.
- The weekly Supertrend indicator is bullish at 1337.54 as of 2026-09-17.
- The monthly Supertrend indicator is bullish at 1101.77 as of 2026-09-17.
- The stock has achieved a 1-year return of 0.72 and a year-to-date return of 0.72.

### Bear Case

The company's recent performance exhibits elevated volatility and significant drawdowns, suggesting potential market caution. While the stock has shown positive returns over longer periods like one year (72%), shorter-term metrics and risk indicators point to increased price fluctuations. The current drawdown stands at -8%, with a maximum drawdown of -19% observed historically. This volatility is further underscored by an annualized volatility of 38% and an Average True Range (ATR) of 3.53% on a daily basis, indicating substantial price swings that investors should monitor.

- The stock has experienced a current drawdown of -8% and a maximum drawdown of -19%.
- Annualized volatility is recorded at 38%, with a daily ATR of 3.53%.
- While the 1-year return is 72%, shorter-term returns and risk metrics suggest heightened price sensitivity.

### FAQs

**What were the key outcomes of Sai Life Sciences Limited's 27th Annual General Meeting (AGM) held on September 17, 2026?**

At the 27th AGM of Sai Life Sciences Limited, held on September 17, 2026, shareholders approved the audited standalone and consolidated financial statements for the year ended March 31, 2026, with approximately 99.9999% of votes in favor. Additionally, Mr. Krishnamraju Kanumuri was re-appointed as a director, receiving approximately 99.0189% of the votes polled.

**What recent investor engagement activities has Sai Life Sciences Limited undertaken?**

Sai Life Sciences Limited participated in investor events in September 2026. The company attended the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026, and was scheduled to participate in the Jefferies 5th India Forum in Gurgaon on September 18, 2026. These events involved group and one-to-one meetings with institutional investors.

**How has Sai Life Sciences Limited's stock performed over different periods, and what is its current technical trend?**

As of September 17, 2026, Sai Life Sciences Limited's stock has shown varied returns across different periods. It had a year-to-date return of 0.72 and a 1-year return of 0.72. Over the last 6 months, the return was 0.57, and over 3 months, it was 0.27. The stock's closing price on September 17, 2026, was ₹1545.7. Technical indicators suggest a bullish trend on daily, weekly, and monthly timeframes, with the Supertrend indicator showing a bullish direction and the closing price trading above key Exponential Moving Averages (EMAs) and Simple Moving Averages (SMAs) across these timeframes.

- Sai Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026 |SUBJECT: Shareholders meeting
- Sai Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results. |SUBJECT: Shareholders meeting
- Sai Life Sciences Limited has informed the Exchange about Schedule of Analysts or Institutional Investors Meet |SUBJECT: Analyst/Investor Meet Para A-XBRL
- Sai Life Sciences Limited has informed the Exchange about Schedule of meet |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates
## Technical analytics

- As of: 2026-09-18
- Daily trend: Strong Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,548.5
- Risk regime: Price Risk Requires Attention

### Support levels
- 1453.2
- 1414.65
- 1216.3

### Resistance levels
- 1697
- 1606.1999999999998

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +3.55% |
| return_10 | +1.63% |
| return_1m | +11.14% |
| return_1y | +78.90% |
| return_20 | +8.76% |
| return_3m | +32.62% |
| return_5 | +0.59% |
| return_6m | +57.86% |
| return_since_start | +111.15% |
| return_ytd | +77.78% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -18.55% |
| annualized_volatility | +38.40% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue and Profit Decline Sequentially but Grow Year-Over-Year

Sai Life Sciences Limited reported a sequential decline in revenue and profitability for the quarter ended 30 June 2026, while year-over-year growth continued. Other expenses rose compared to the previous quarter, contributing to margin compression, but finance costs declined both sequentially and over the past year, supporting profitability. The effective tax rate remained stable.

## Revenue

Revenue from operations was ₹554.29 crore, a sequential decrease of ₹47.85 crore (7.95%) from ₹602.14 crore in the preceding quarter. Compared with the same quarter a year ago, revenue increased by ₹57.87 crore (11.66%) from ₹496.42 crore. The business therefore experienced a quarterly dip from the recent high while maintaining year-over-year expansion.

## Profitability and Margins

Profit before tax (PBT) fell to ₹97.97 crore, down ₹41.25 crore (29.63%) sequentially from ₹139.23 crore. The PBT margin contracted from 23.12% in the prior quarter to 17.68% in the current quarter. Net profit followed a similar pattern, declining to ₹73.29 crore from ₹104.24 crore sequentially.

On a year-over-year basis, PBT rose by ₹17.23 crore (21.33%) from ₹80.75 crore, and the PBT margin expanded from 16.27% to 17.68%. Net profit increased from ₹60.46 crore to ₹73.29 crore over the same period.

The effective tax rate was approximately 25.2%, consistent with recent quarters.

## Expense Movements

Other expenses increased to ₹81.47 crore, a sequential rise of ₹4.24 crore (5.49%) from ₹77.23 crore, moving in the opposite direction to revenue. Year-over-year, other expenses grew by 10.46% from ₹73.76 crore, broadly in line with revenue growth.

Finance costs continued to decline, falling by ₹0.19 crore (2.42%) sequentially to ₹7.64 crore. Over the past year, finance costs dropped by ₹4.73 crore (38.24%) from ₹12.36 crore, providing a meaningful tailwind to profitability.

## Management Commentary

Sai Life Sciences reported a strong start to FY27, with Q1 revenue up 12% YoY to ₹554 Cr and net profit up 22% YoY to ₹73 Cr. Management highlighted that large pharmaceutical companies are increasingly seeking integrated discovery and development partners, and Sai Life’s technology base, scientific talent, and culture are driving strategic multi-year engagements. The CRO business grew 24% YoY, while the CDMO CMC pipeline strengthened to 33 active commercial molecules and 14 late-phase molecules, with encouraging traction in the FTE-led engagement model.

CFO Siva Chittor noted a healthy balance sheet and disciplined capital allocation. The company operationalized a new 100,000 sq. ft. R&D facility at Genome Valley and achieved an EcoVadis Platinum rating for sustainability, placing it in the top 1% of assessed companies globally. Management remains confident in executing its long-term growth strategy.

## Key Takeaway

The quarter was marked by sequential declines in revenue and profit from a strong prior quarter, while year-over-year growth remained intact. The sequential margin compression coincided with an increase in other expenses, and a sustained reduction in finance costs supported annual profitability. The effective tax rate was stable.

### Ratios

## Official filings

- 2026-09-18 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20260918_181226322.xml)
- 2026-09-18 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_18092026181531_Stx_Intimation_ESOP_Allotment_Signed.pdf)
- 2026-09-17 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_17092026125920_Stx_Intimation_Outcome_Proceedings_Signed.pdf)
- 2026-09-17 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_17092026164103_Stx_Intimation_Voting_Results_Signed.pdf)
- 2026-09-04 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20260904_164319118.xml)
- 2026-09-04 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_04092026165603_StxIntimationInvestorAnalystMeetSigned.pdf)
- 2026-09-04 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20260904_165000464.xml)
- 2026-09-04 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_04092026170151_StxIntimationInvestorAnalystMeetSigned.pdf)
- 2026-08-26 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_26082026105857_Stx_Intimation_Postdispatch_Signed.pdf)
- 2026-08-25 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_24081_WebXMLFile_20260825_183534232.xml)
- 2026-08-24 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_24082026131610_Stx_Initial_AGM_Intimation_Signed.pdf)
- 2026-08-24 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_24082026131840_Stx_Predispatch_AGM_Intimation_Signed.pdf)
- 2026-08-12 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20260812_161058885.xml)
- 2026-08-12 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_12082026135133_Stx_Intimation_ECT_12082026_Signed.pdf)
- 2026-08-08 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_08082026133514_Newspaper_Publication.pdf)
- 2026-08-07 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_07082026184828_Earnigs_Call_Recording.pdf)
- 2026-08-07 — Credit Rating Update: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_07082026221212_Monitoring_Agency_Report.pdf)
- 2026-08-07 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20260807_191308530.xml)
- 2026-08-07 — Earnings Presentation: Sai Life Sciences Limited filed an investor presentation for the quarter ended June 30, 2026, on August 7, 2026. The company reported Q1 FY27 revenue of ₹554 crore, a 12% year-on-year increase, with EBITDA at ₹148 crore and PAT at ₹73 crore. The CRO business grew 24% year-on-year, and the company incurred capital expenditure of ₹263 crore. — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_07082026135318_Investor_Presentation.pdf)
- 2026-08-06 — Generic Announcement: Sai Life Sciences Limited's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, on August 6, 2026. The company reported total income of Rs. 5,502.72 million and a profit after tax of Rs. 713.39 million for the standalone entity for the quarter. The consolidated total income was Rs. 5,578.28 million with a profit after tax of Rs. 732.85 million. The statutory auditors, Deloitte Haskins & Sells LLP, issued an unmodified conclusion on their limited review. — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06082026223607_Outcome.pdf)
- 2026-08-06 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20260806_235602690.xml)
- 2026-08-06 — Press Release: Sai Life Sciences Limited reported its un-audited financial results for the quarter ended June 30, 2026. Revenue from operations was ₹554 crore, a 12% year-on-year increase, with Profit After Tax (PAT) at ₹73 crore, up 22% year-on-year. The company also operationalized a new 100,000 sq. ft. R&D facility in Hyderabad and achieved an EcoVadis Platinum Rating. — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06082026232256_Press_Release.pdf)
- 2026-08-06 — Generic Announcement: On August 6, 2026, Sai Life Sciences Limited allotted 18,700 fully paid-up equity shares under its Employees Stock Option Plan 2008. The exercise price per share was Rs. 188.90, resulting in Rs. 35,32,430 realized from the exercise of these options. — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06082026235453_Intimation_of_Allotment.pdf)
- 2026-08-04 — Generic Announcement: Sai Life Sciences Limited will hold meetings with analysts and investors on August 13 and 14, 2026, in Singapore. The meetings are part of the Avendus Spark INDX-Asia Edition 2026 event and will be conducted as one-on-one or group sessions. The company will not discuss any unpublished price-sensitive information or present new materials during these meetings. — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_04082026211235_Sai_Meeting_Intimation_13_14_August2026_.pdf)
- 2026-08-04 — Official Filing: SAI LIFE SCIENCES LIMITED (NSE: SAILIFE) will participate in the Avendus Spark INDX-Asia Edition 2026 event in Singapore. The company will hold analyst meetings on August 13, 2026, and August 14, 2026, both starting at 10:00 AM. These meetings will be in-person and include one-on-one and/or group sessions with various analysts and institutional investors.

## News and market events

- 2026-09-10 — CNBC-TV18: **IRB Infra, Ola Electric lead Nifty 500 gainers; HEG, Craftsman Automation fall at market open** — Monthly toll revenue data was among the reasons that moved a stock over 5% on the Nifty 500 at market open, while one stock extending its decline toward a fresh 52-week low — here's a look at today's top gainers and losers. — [Source](https://www.cnbctv18.com/market/stocks/irb-infrastructure-ola-electric-nifty-500-gainers-heg-craftsman-automation-sai-life-sciences-share-price-19988093.htm)
- 2026-09-02 — News18: **Market Crash Today: 10 Stocks Defy Selloff, Rally Up To 8% on September 2** — IFCI is among the biggest gainers, surging 8.02% to Rs 94.26, followed by The New India Assurance Company, up 5.67% at Rs 196.3, and Poly Medicure, which gains 5.48% to Rs 1,852.6. — [Source](https://www.news18.com/business/markets/market-crash-today-10-stocks-defy-selloff-rally-up-to-8-on-september-2-ws-l-10305500.html)
- 2026-09-02 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —2 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —GHCL Textiles, Gmm Pfaudler, Tarsons Products, Aeroflex Industries, and Sai Life Sciences. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-2-september-2026-11788310076025.html)
- 2026-08-27 — MONEYCONTROL: **Goldman Sachs-backed CRDMO Aragen Life Sciences files IPO papers to raise Rs 800 crore fresh capital** — Aragen Life Sciences IPO size,Aragen Life Sciences IPO DRHP,Aragen Life Sciences IPO news,Aragen Life Sciences IPO details,Goldman Sachs — [Source](https://www.moneycontrol.com/news/business/ipo/goldman-sachs-backed-crdmo-aragen-life-sciences-files-ipo-papers-to-raise-rs-800-crore-fresh-capital-14017035.html)
- 2026-08-26 — Mint: **Buy or sell: Gift Nifty signals gap-up start | Vaishali Parekh recommends three stocks to buy today — 26 August 2026** — Buy or sell indicator: Vaishali Parekh recommends three stocks to buy today — Astral, Sai Life Sciences, and ICICI Bank — [Source](https://www.livemint.com/market/stock-market-news/buy-or-sell-gift-nifty-signals-gap-up-start-vaishali-parekh-recommends-three-stocks-to-buy-today-26-august-2026-11787709370297.html)
- 2026-08-21 — MONEYCONTROL: **Trade Spotlight: How should you trade Sai Life Sciences, EID Parry, Raymond, Glenmark Pharma, MCX India, and others on August 21?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Sai Life Sciences,Shriram Finance,EID Parry (India),Raymond,Glenmark Pharmaceuticals,Multi Commodity Exchange of India, — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-sai-life-sciences-eid-parry-raymond-glenmark-pharma-mcx-india-and-others-on-august-21-14011993.html)
- 2026-07-22 — CNBC-TV18: **Donald Trump to impose 100% tariff on generic pharma imports from 2028, 200% a year later** — Trump's earlier tariffs in this sector pertained to branded and patented drugs, the policy of which has been left unchanged. The earlier policy had left out generic drugs, as nearly 90% of the US prescriptions comprise of them. — [Source](https://www.cnbctv18.com/market/sun-pharma-lupin-cipla-biocon-share-price-donald-trump-generic-drugs-tariffs-timeline-impact-19950953.htm)
- 2026-07-20 — Mint: **Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street** — Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each. — [Source](https://www.livemint.com/market/stock-market-news/cipla-ajanta-pharma-to-alkem-laboratories-pharma-stocks-rise-amid-weak-trends-on-dalal-street-11784531087488.html)

## Business profile

**Strategic vision:** CRDMO partnering with pharma and biotech for drug development.

### Business segments
- **Discovery Services:** Provides chemistry, biology, DMPK, and toxicology services to aid clients in identifying and optimizing lead drug candidates.
- **Development & Manufacturing:** Supports clinical development and commercial manufacturing through process R&D, analytical method development, and API manufacturing in cGMP-compliant facilities.

### Competitive strengths
- Integrated CRDMO services across discovery, development, and manufacturing.
- cGMP compliant manufacturing facilities for API production.

## Related stocks

- [ABBOTINDIA (Healthcare)](https://faxioms.com/stocks/abbotindia) — +5.50%
- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/sailife
Markdown representation: https://faxioms.com/stocks/sailife?render=md